



ST VINCENT'S  
HEALTH AUSTRALIA

# Long Acting Buprenorphine

Victorian Opioid Management ECHO  
Department of Addiction Medicine  
St Vincent's Hospital Melbourne 2019


UNDER THE STEWARDSHIP OF MARY AIKENHEAD MINISTRIES

# Buprenorphine – Principles

---

- Has high affinity for the opioid receptor
- Competes with other opioids for the receptors
- Binds to receptors *in preference* to full opioid agonists
- Has limited opioid effect, stopping withdrawal but not causing euphoria
- At 24 -72 hours, begins to dissipate from receptors
- Partial Agonist – similar to full agonists at low doses, however cause less receptor activation, and at high doses analgesic effects plateau.

# Opiate Agonists – Principle



# Unmet needs

---

OAT has demonstrated effectiveness.

- Reduces illicit opioid use

- Reduces spread of BBV

- Improved mortality

- Reduces Crime

Limitations:

- Need better effectiveness

- Need to improve safety – accidental exposure, diversion

- Need to improve uptake of treatment – inconvenient, cost, stigma of daily meds

# BUVIDAL

---

Newly created FluidCrystal depot injection

Flexible dosing across all OAT phases

Ready-to-use prefilled syringe

Small volume dosing (.16-.64mL)

Fine gauge needle



Room temperature stable – does not need special refrigeration

Dosing regimens of either weekly or monthly



## The FluidCrystal® drug delivery system

- Lipid based drug delivery system
  - Glycerol dioleate (GDO) & soy Phosphatidylcholine (PC)
  - Solvents ethanol (q1w) or N-Methyl Pyrrolidine (NMP) (q4w)
- Rapid start of release after injection (direct induction possible)
- ~1500 subjects who have received >15,000 injections in clinical trials



# Conversions

## Dose conversion for switching between CAM2038 and SL BPN

Daily SL BPN Dose	CAM2038 q1w	CAM2038 q4w
< 6 mg	8 mg	–
8 – 10 mg	16 mg	64 mg
12 – 16 mg	24 mg	96 mg
18 – 24 mg	32 mg	128 mg
26 – 32 mg	–	160 mg

**NOTE: The 160mg monthly injection is not currently registered in Australia**


# Satisfaction

camurus.

## Patient satisfaction with CAM2038 compared to previous SL BPN/BNX (Study 499)

The study medication compared to my previously prescribed SL BPN treatment is:

Patients transferring from sublingual BPN (N=133)



15

Reference: Presentations at APSAD 2017, ASAM 2018, CPDD 2018



# SUBLOCADE

---

Once monthly depot injection

Must be refrigerated for storage. Only shelf stable for 7 days

Must be allowed to warm to room temperature before injection (at least 15 minutes)

Pre-filled syringe

Single regimen with small amount of flexibility

Monthly only – 300mg, 300mg, maintain on 100mg

- Can continue 300mg monthly if unsatisfactory symptom control on 100mg



# Initiation

---

Both products require a period of stabilisation on Sublingual Buprenorphine before commencing

Buvidal can be started as weekly at first, or straight to monthly

# Availability

---

Neither product currently available for prescription or dispensing

Will be dispensed/administered by medical practitioner/nurse practitioner only

No need for patient to attend pharmacy to obtain medication

Both buprenorphine products will require MATOD permit for prescribing

Sublocade predicted availability in Second half 2019 (may need SAS to obtain access)

Buvidal predicted limited availability late May 2019

# Limited Availability??

---

Initial 6 month product familiarisation phase

Available only to specific prescribers (still requires permit)

- GP/NP with >5 years experience as pharmacotherapy prescribers working in accredited practices
- MATOD trained
- Must have permit to store Schedule 8 medications on site
- Approved site:
  - Specialist pharmacotherapy services
  - Specialist clinics with access to counselling within the clinic
  - Hospital based Addiction medicine services
  - Rural and regional hospitals with access to addiction medicine specialists
  - Any service with addiction medicine specialists or addiction psychiatrists attached.
- Each prescriber will have limited numbers of permits during PFP

# And after the PFP?

---

Predicted to be available to all MATOD certified prescribers after the PFP has been completed.

# Summary

---

Two products soon to be available

Buvidal – range of weekly and monthly dosages

Sublocade – two monthly dosages – initiation and maintenance

Initial Product Familiarisation Phase followed by access to MATOD prescribers.

